NCT03200184View on ClinicalTrials.gov

Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

1,448

Participants

Timeline

Start Date

September 1, 2016

Primary Completion Date

April 1, 2018

Study Completion Date

September 1, 2018

Conditions

Hepatitis C

Interventions

DRUG

sofosbuvir and daclatasvir

A fixed dose combination pill containing 400mg sofosbuvir and 60 mg daclatasvir given daily for 12 weeks. If a patient is cirrhotic, treatment duration would be 24 weeks.

Trial Locations (1)

14117

Shariati Hospital, Tehran

All Listed Sponsors

lead

Tehran University of Medical Sciences

OTHER

NCT03200184 - Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients | Biotech Hunter | Biotech Hunter